AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00373399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC marijuana (3.9% THC)
Description: Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
Study NCT01549431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks
Study NCT01549431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks
Study NCT01549431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
Study NCT00962195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: purple sweet potato (PSP)-juice
Description: Daily oral intake of 3x 125 ml of PSP-juice or control juice
Study NCT00962195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: purple sweet potato (PSP)-juice
Description: Daily oral intake of 3x 125 ml of PSP-juice or control juice
Study NCT04523987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
Study NCT02324218 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data extraction from CPRD database of UK.
Study NCT01469533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal mechanical manipulation intervention
Description: Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (\<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
Study NCT01469533 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation intervention
Description: Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
Study NCT04731454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet (CD)
Description: All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. A sugar-sweetened juice drink was provided for consumption of one portion per day. Water, milk, coffee, tea and alcohol were consumed as usual.
Study NCT04731454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Nordic Diet (ND)
Description: All food was provided to participants for the duration of the intervention (8 days), including prepared lunches and dinners and ingredients for breakfasts and snacks. Water, milk, coffee, tea and alcohol were consumed as usual.
Study NCT02178748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Single dose of 1x10\^8pfu MVA85A intramuscular vaccination
Study NCT03633968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary sinus lift
Description: maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
Study NCT02744222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-054 180 mcg
Description: 180 mcg intramuscularly once every two weeks
Study NCT02744222 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: 30 mcg intramuscularly once a week
Study NCT02744222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-054 240 mcg
Description: 240 mcg intramuscularly once every two weeks
Study NCT02744222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscularly once a week (0,5 ml)
Study NCT02795273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grass-SPIRE
Study NCT02795273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00446810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benfotiamine
Study NCT00446810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01615328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervios ChronOs
Description: The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
Study NCT01615328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonion
Description: The ACDF surgery will be carried out with Bonion after randomization procedure.
Study NCT03548298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARAT
Description: After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
Study NCT00082173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400mg daily for 8 weeks
Study NCT00082173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg daily for 8 weeks
Study NCT00746590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolarix (tretazicar co-administered with caricotamide)
Description: Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
Study NCT04453280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 diagnostic rapid test
Description: The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
Study NCT02976441 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT02976441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02976441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell collection
Study NCT02976441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study NCT02606903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 prefilled syringe
Study NCT02606903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 autoinjector
Study NCT03527225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
Study NCT05283967 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine colorimetric assay
Description: Colorimetric assays will be performed for urine drug concentrations of rifampin, isoniazid and pyrazinamide from urine collected throughout one dosing interval. Assay results will experimental only and not used to change patient care.
Study NCT02421484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells
Description: The allogeneic mesenchymal stromal cells will be administered intravenously.
Study NCT00906841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-hLL2
Description: Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
Study NCT01973660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT01973660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01973660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Letrozole or tamoxifen will be prescribed according to patient's menopausal status
Study NCT01973660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Only administrated if tumor progression is observed by US on week 6
Study NCT02548455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quartet 1457Q LV Lead
Study NCT03881306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-TACE
Description: D-TACE with CalliSpheres-Oxaliplatin
Study NCT01154920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135 mg/m\^2 weekly, Weeks 1 - 6
Study NCT01154920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 2 weekly, Weeks 1 - 6
Study NCT01154920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: PCC Arm: 400 mg/m\^2 by vein over about 1-2 hours on Day 1; 250 mg/m\^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8.
Study NCT01154920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
Study NCT01154920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
Study NCT01154920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 700 mg/m\^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
Study NCT01154920 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
Study NCT01154920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m\^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
Study NCT03568266 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of saliva
Study NCT03357874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
Study NCT03357874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
Study NCT04022200 — intervention group
Intervention type: DEVICE
Intervention: Paclitaxel DCB
Description: The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
Study NCT00464815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose
Study NCT00464815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One subcutaneous dose
Study NCT04184726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
Study NCT04237571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CANE Meal Program
Description: Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
Study NCT01517763 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional CPAP Therapy
Description: HC244 devices without Thermosmart or SensAwake
Study NCT01517763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed pressure ICON™ without ThermoSmart™
Description: Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
Study NCT01517763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto ICON™ with SensAwake™ and ThermoSmart™
Description: APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
Study NCT00542399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levemir (insulin detemir)
Description: Levemir once a day
Study NCT00542399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levemir twice a day
Description: Levemir twice a day
Study NCT02112630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-IFN alfa 2a
Description: P-IFN alfa 2b 0.75 mcg/kg/week
Study NCT02112630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-IFN alfa 2b
Description: P-IFN alfa 2a 135 mcg/kg/week
Study NCT02112630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg PO once daily or 200 mg PO three times a week
Study NCT02112630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg PO three times daily starting at week 4
Study NCT03024957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
Study NCT03024957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
Study NCT03024957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
Study NCT01017133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: fludeoxyglucose F 18
Description: Given IV
Study NCT01017133 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Fluorine F 18 EF5
Description: Given IV
Study NCT01017133 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron emission tomography
Description: Undergo scan
Study NCT02196441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% tetracaine local anaesthetic drops
Description: topical anaesthetic drops
Study NCT02196441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
Study NCT02893033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS
Study NCT02893033 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS
Study NCT01732640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
Study NCT01732640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
Study NCT01732640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
Study NCT01732640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
Study NCT01732640 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
Study NCT04161404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules
Description: Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
Study NCT04161404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg
Description: Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
Study NCT04161404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage) 1000mg
Description: Metformin is an oral glucose-lowering drug of the biguanides class. Drug: Period 1 Subjects
Study NCT03236961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
Study NCT03236961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: P.o. moxifloxacin 400 mg x1 for 7 days
Study NCT01437254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPERT
Description: Single 340 MBq CPERT scan in first 10 subjects
Study NCT01437254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GPERT
Description: Single 340 MBq GPERT scan in up to 20 case-matched controls
Study NCT02395848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: 200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
Study NCT03193320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy protocol
Description: Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.